2004Medical Entomology and ZoologyRequires access

Acquired Long QT Syndrome

A. John Camm, Marek Malík, Yee Guan Yap

Open publisher page 47 citations

Abstract

Chapter 1. Introduction.Chapter 2. Mechanisms of Acquired QT Prolongation and Torsades de Pointes.Chapter 3. Measurement of QT Interval and Repolarization Assessment.Chapter 4: Introduction to Drug-Induced Long QT Syndrome.Chapter 5: Risk of QT Prolongation and Torsades de Pointes with Antiarrhythmic Drugs.Chapter 6: Risk of QT Prolongation and Torsades de Pointes with Antihistamines.Chapter 7: Risk of QT Prolongation and Torsades de Pointes with Psychotrophic Drugs.Chapter 8: Risk of QT Prolongation and Torsades de Pointes with Antimicrobial and Antimalarial Drugs.Chapter 9: Risk of QT Prolongation and Torsades de Pointes with Prokinetics and Miscellaneous.Chapter 10: Acquired Long QT Syndrome Secondary to Cardiac Conditions.Chapter 11: Acquired Long QT Syndrome Secondary to Noncardiac Conditions.Chapter 12: Preclinical and Clinical Assessment of the Risk of QT Prolongation and Torsades de Pointes with New Active Substances.Chapter 13: Conclusion and Perspective of Drug-Induced Repolarization Changes

About this research paper

What this paper is about

Chapter 1. Introduction.Chapter 2. Mechanisms of Acquired QT Prolongation and Torsades de Pointes.Chapter 3. Measurement of QT Interval and Repolarization Assessment.Chapter 4: Introduction to Drug-Induced Long QT Syndrome.Chapter 5: Risk of QT Prolongation and Torsades de Pointes with Antiarrhythmic Drugs.Chapter 6: Risk of QT Prolongation and Torsades de Pointes with Antihistamines.Chapter 7: Risk of QT Prolongation and Torsades de Pointes with Psychotrophic Drugs.Chapter 8: Risk of QT Prolongation and Torsades de Pointes with Antimicrobial and Antimalarial Drugs.Chapter 9: Risk of QT Prolongation and Torsades de Pointes with Prokinetics and Miscellaneous.Chapter 10: Acquired Long QT Syndrome Secondary to Cardiac Conditions.Chapter 11: Acquired Long QT Syndrome Secondary to Noncardiac Conditions.Chapter 12: Preclinical and Clinical Assessment of the Risk of QT Prolongation and Torsades de Pointes with New Active Substances.Chapter 13: Conclusion and Perspective of Drug-Induced Repolarization Changes

Why it matters

OpenAlex reports 47 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Chapter 1. Introduction.Chapter 2. Mechanisms of Acquired QT Prolongation and Torsades de Pointes.Chapter 3. Measurement of QT Interval and Repolarization Assessment.Chapter 4: Introduction to Drug-Induced Long QT Syndrome.Chapter 5: Risk of QT Prolongation and Torsades de Pointes with Antiarrhythmic Drugs.Chapter 6: Risk of QT Prolongation and Torsades de Pointes with Antihistamines.Chapter 7: Risk of QT Prolongation and Torsades de Pointes with Psychotrophic Drugs.Chapter 8: Risk of QT Prolongation and Torsades de Pointes with Antimicrobial and Antimalarial Drugs.Chapter 9: Risk of QT Prolongation and Torsades de Pointes with Prokinetics and Miscellaneous.Chapter 10: Acquired Long QT Syndrome Secondary to Cardiac Conditions.Chapter 11: Acquired Long QT Syndrome Secondary to Noncardiac Conditions.Chapter 12: Preclinical and Clinical Assessment of the Risk of QT Prolongation and Torsades de Pointes with New Active Substances.Chapter 13: Conclusion and Perspective of Drug-Induced Repolarization Changes

Key concepts: Torsades de pointes, QT interval, Prolongation, Medicine, Long QT syndrome, Cardiology, Repolarization, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Acquired Long QT Syndrome — Research Paper | ScholarLens